nodes	percent_of_prediction	percent_of_DWPC	metapath
Trametinib—CYP2C8—Tretinoin—peripheral nervous system neoplasm	0.108	0.366	CbGbCtD
Trametinib—CYP3A4—Topotecan—peripheral nervous system neoplasm	0.0471	0.159	CbGbCtD
Trametinib—CYP2C8—Etoposide—peripheral nervous system neoplasm	0.0454	0.154	CbGbCtD
Trametinib—CYP3A4—Tretinoin—peripheral nervous system neoplasm	0.0437	0.148	CbGbCtD
Trametinib—CYP3A4—Vincristine—peripheral nervous system neoplasm	0.0201	0.0681	CbGbCtD
Trametinib—CYP3A4—Etoposide—peripheral nervous system neoplasm	0.0184	0.0624	CbGbCtD
Trametinib—CYP3A4—Doxorubicin—peripheral nervous system neoplasm	0.0126	0.0425	CbGbCtD
Trametinib—Hyponatraemia—Epirubicin—peripheral nervous system neoplasm	0.000287	0.000772	CcSEcCtD
Trametinib—Renal failure acute—Doxorubicin—peripheral nervous system neoplasm	0.000287	0.000771	CcSEcCtD
Trametinib—Diarrhoea—Melphalan—peripheral nervous system neoplasm	0.000286	0.00077	CcSEcCtD
Trametinib—Pain in extremity—Epirubicin—peripheral nervous system neoplasm	0.000286	0.000769	CcSEcCtD
Trametinib—Myalgia—Cisplatin—peripheral nervous system neoplasm	0.000286	0.000768	CcSEcCtD
Trametinib—Anaemia—Etoposide—peripheral nervous system neoplasm	0.000284	0.000764	CcSEcCtD
Trametinib—Unspecified disorder of skin and subcutaneous tissue—Cisplatin—peripheral nervous system neoplasm	0.000284	0.000763	CcSEcCtD
Trametinib—Gastrointestinal pain—Dactinomycin—peripheral nervous system neoplasm	0.000283	0.000762	CcSEcCtD
Trametinib—Dizziness—Topotecan—peripheral nervous system neoplasm	0.000283	0.00076	CcSEcCtD
Trametinib—Musculoskeletal discomfort—Vincristine—peripheral nervous system neoplasm	0.000282	0.000759	CcSEcCtD
Trametinib—Dizziness—Tretinoin—peripheral nervous system neoplasm	0.00028	0.000754	CcSEcCtD
Trametinib—Dizziness—Isotretinoin—peripheral nervous system neoplasm	0.00028	0.000754	CcSEcCtD
Trametinib—Insomnia—Vincristine—peripheral nervous system neoplasm	0.00028	0.000753	CcSEcCtD
Trametinib—Decreased appetite—Alitretinoin—peripheral nervous system neoplasm	0.000279	0.000751	CcSEcCtD
Trametinib—Gastrointestinal disorder—Alitretinoin—peripheral nervous system neoplasm	0.000277	0.000746	CcSEcCtD
Trametinib—Fatigue—Alitretinoin—peripheral nervous system neoplasm	0.000277	0.000745	CcSEcCtD
Trametinib—Leukopenia—Etoposide—peripheral nervous system neoplasm	0.000275	0.00074	CcSEcCtD
Trametinib—Constipation—Alitretinoin—peripheral nervous system neoplasm	0.000275	0.000739	CcSEcCtD
Trametinib—Abdominal pain—Dactinomycin—peripheral nervous system neoplasm	0.000274	0.000737	CcSEcCtD
Trametinib—Body temperature increased—Dactinomycin—peripheral nervous system neoplasm	0.000274	0.000737	CcSEcCtD
Trametinib—Oedema—Cisplatin—peripheral nervous system neoplasm	0.000274	0.000736	CcSEcCtD
Trametinib—Infection—Cisplatin—peripheral nervous system neoplasm	0.000272	0.000731	CcSEcCtD
Trametinib—Vomiting—Topotecan—peripheral nervous system neoplasm	0.000272	0.000731	CcSEcCtD
Trametinib—Vomiting—Tretinoin—peripheral nervous system neoplasm	0.00027	0.000725	CcSEcCtD
Trametinib—Vomiting—Isotretinoin—peripheral nervous system neoplasm	0.00027	0.000725	CcSEcCtD
Trametinib—Rash—Topotecan—peripheral nervous system neoplasm	0.000269	0.000725	CcSEcCtD
Trametinib—Dermatitis—Topotecan—peripheral nervous system neoplasm	0.000269	0.000724	CcSEcCtD
Trametinib—Decreased appetite—Vincristine—peripheral nervous system neoplasm	0.000269	0.000724	CcSEcCtD
Trametinib—Nervous system disorder—Cisplatin—peripheral nervous system neoplasm	0.000268	0.000722	CcSEcCtD
Trametinib—Cough—Etoposide—peripheral nervous system neoplasm	0.000268	0.000721	CcSEcCtD
Trametinib—Thrombocytopenia—Cisplatin—peripheral nervous system neoplasm	0.000268	0.000721	CcSEcCtD
Trametinib—Blood creatinine increased—Epirubicin—peripheral nervous system neoplasm	0.000268	0.000721	CcSEcCtD
Trametinib—Headache—Topotecan—peripheral nervous system neoplasm	0.000268	0.00072	CcSEcCtD
Trametinib—Rash—Tretinoin—peripheral nervous system neoplasm	0.000267	0.000719	CcSEcCtD
Trametinib—Rash—Isotretinoin—peripheral nervous system neoplasm	0.000267	0.000719	CcSEcCtD
Trametinib—Gastrointestinal disorder—Vincristine—peripheral nervous system neoplasm	0.000267	0.000719	CcSEcCtD
Trametinib—Dermatitis—Tretinoin—peripheral nervous system neoplasm	0.000267	0.000718	CcSEcCtD
Trametinib—Dermatitis—Isotretinoin—peripheral nervous system neoplasm	0.000267	0.000718	CcSEcCtD
Trametinib—Fatigue—Vincristine—peripheral nervous system neoplasm	0.000267	0.000718	CcSEcCtD
Trametinib—Vomiting—Melphalan—peripheral nervous system neoplasm	0.000266	0.000716	CcSEcCtD
Trametinib—Dehydration—Epirubicin—peripheral nervous system neoplasm	0.000266	0.000715	CcSEcCtD
Trametinib—Skin disorder—Cisplatin—peripheral nervous system neoplasm	0.000266	0.000715	CcSEcCtD
Trametinib—Hyponatraemia—Doxorubicin—peripheral nervous system neoplasm	0.000266	0.000715	CcSEcCtD
Trametinib—Headache—Tretinoin—peripheral nervous system neoplasm	0.000266	0.000714	CcSEcCtD
Trametinib—Headache—Isotretinoin—peripheral nervous system neoplasm	0.000266	0.000714	CcSEcCtD
Trametinib—Hypertension—Etoposide—peripheral nervous system neoplasm	0.000265	0.000714	CcSEcCtD
Trametinib—Constipation—Vincristine—peripheral nervous system neoplasm	0.000265	0.000712	CcSEcCtD
Trametinib—Pain in extremity—Doxorubicin—peripheral nervous system neoplasm	0.000265	0.000712	CcSEcCtD
Trametinib—Hyperhidrosis—Cisplatin—peripheral nervous system neoplasm	0.000265	0.000712	CcSEcCtD
Trametinib—Rash—Melphalan—peripheral nervous system neoplasm	0.000264	0.00071	CcSEcCtD
Trametinib—Dermatitis—Melphalan—peripheral nervous system neoplasm	0.000264	0.000709	CcSEcCtD
Trametinib—Gastrointestinal pain—Alitretinoin—peripheral nervous system neoplasm	0.000263	0.000707	CcSEcCtD
Trametinib—Dry skin—Epirubicin—peripheral nervous system neoplasm	0.000262	0.000705	CcSEcCtD
Trametinib—Abdominal pain upper—Epirubicin—peripheral nervous system neoplasm	0.000261	0.000703	CcSEcCtD
Trametinib—Hypokalaemia—Epirubicin—peripheral nervous system neoplasm	0.00026	0.0007	CcSEcCtD
Trametinib—Unspecified disorder of skin and subcutaneous tissue—Etoposide—peripheral nervous system neoplasm	0.00026	0.000699	CcSEcCtD
Trametinib—Aspartate aminotransferase increased—Epirubicin—peripheral nervous system neoplasm	0.000258	0.000693	CcSEcCtD
Trametinib—Abdominal pain—Alitretinoin—peripheral nervous system neoplasm	0.000254	0.000683	CcSEcCtD
Trametinib—Body temperature increased—Alitretinoin—peripheral nervous system neoplasm	0.000254	0.000683	CcSEcCtD
Trametinib—Nausea—Topotecan—peripheral nervous system neoplasm	0.000254	0.000683	CcSEcCtD
Trametinib—Gastrointestinal pain—Vincristine—peripheral nervous system neoplasm	0.000253	0.000681	CcSEcCtD
Trametinib—Alanine aminotransferase increased—Epirubicin—peripheral nervous system neoplasm	0.000252	0.000678	CcSEcCtD
Trametinib—Nausea—Tretinoin—peripheral nervous system neoplasm	0.000252	0.000677	CcSEcCtD
Trametinib—Nausea—Isotretinoin—peripheral nervous system neoplasm	0.000252	0.000677	CcSEcCtD
Trametinib—Musculoskeletal discomfort—Cisplatin—peripheral nervous system neoplasm	0.000249	0.000671	CcSEcCtD
Trametinib—Infection—Etoposide—peripheral nervous system neoplasm	0.000249	0.00067	CcSEcCtD
Trametinib—Asthenia—Dactinomycin—peripheral nervous system neoplasm	0.000249	0.000669	CcSEcCtD
Trametinib—Nausea—Melphalan—peripheral nervous system neoplasm	0.000249	0.000668	CcSEcCtD
Trametinib—Blood creatinine increased—Doxorubicin—peripheral nervous system neoplasm	0.000248	0.000667	CcSEcCtD
Trametinib—Dehydration—Doxorubicin—peripheral nervous system neoplasm	0.000246	0.000662	CcSEcCtD
Trametinib—Thrombocytopenia—Etoposide—peripheral nervous system neoplasm	0.000246	0.00066	CcSEcCtD
Trametinib—Body temperature increased—Vincristine—peripheral nervous system neoplasm	0.000245	0.000658	CcSEcCtD
Trametinib—Abdominal pain—Vincristine—peripheral nervous system neoplasm	0.000245	0.000658	CcSEcCtD
Trametinib—Skin disorder—Etoposide—peripheral nervous system neoplasm	0.000244	0.000655	CcSEcCtD
Trametinib—Dry skin—Doxorubicin—peripheral nervous system neoplasm	0.000243	0.000652	CcSEcCtD
Trametinib—Hyperhidrosis—Etoposide—peripheral nervous system neoplasm	0.000242	0.000652	CcSEcCtD
Trametinib—Pancreatitis—Epirubicin—peripheral nervous system neoplasm	0.000242	0.000652	CcSEcCtD
Trametinib—Abdominal pain upper—Doxorubicin—peripheral nervous system neoplasm	0.000242	0.00065	CcSEcCtD
Trametinib—Hypokalaemia—Doxorubicin—peripheral nervous system neoplasm	0.000241	0.000648	CcSEcCtD
Trametinib—Aspartate aminotransferase increased—Doxorubicin—peripheral nervous system neoplasm	0.000238	0.000641	CcSEcCtD
Trametinib—Decreased appetite—Cisplatin—peripheral nervous system neoplasm	0.000238	0.00064	CcSEcCtD
Trametinib—Diarrhoea—Dactinomycin—peripheral nervous system neoplasm	0.000237	0.000638	CcSEcCtD
Trametinib—Gastrointestinal disorder—Cisplatin—peripheral nervous system neoplasm	0.000236	0.000636	CcSEcCtD
Trametinib—Alanine aminotransferase increased—Doxorubicin—peripheral nervous system neoplasm	0.000233	0.000628	CcSEcCtD
Trametinib—Neutropenia—Epirubicin—peripheral nervous system neoplasm	0.000231	0.000622	CcSEcCtD
Trametinib—Asthenia—Alitretinoin—peripheral nervous system neoplasm	0.00023	0.00062	CcSEcCtD
Trametinib—Pruritus—Alitretinoin—peripheral nervous system neoplasm	0.000227	0.000611	CcSEcCtD
Trametinib—Pancreatitis—Doxorubicin—peripheral nervous system neoplasm	0.000224	0.000603	CcSEcCtD
Trametinib—Hyperglycaemia—Epirubicin—peripheral nervous system neoplasm	0.000223	0.0006	CcSEcCtD
Trametinib—Asthenia—Vincristine—peripheral nervous system neoplasm	0.000222	0.000597	CcSEcCtD
Trametinib—Infestation—Epirubicin—peripheral nervous system neoplasm	0.00022	0.000593	CcSEcCtD
Trametinib—Infestation NOS—Epirubicin—peripheral nervous system neoplasm	0.00022	0.000593	CcSEcCtD
Trametinib—Vomiting—Dactinomycin—peripheral nervous system neoplasm	0.00022	0.000593	CcSEcCtD
Trametinib—Diarrhoea—Alitretinoin—peripheral nervous system neoplasm	0.00022	0.000591	CcSEcCtD
Trametinib—Rash—Dactinomycin—peripheral nervous system neoplasm	0.000218	0.000588	CcSEcCtD
Trametinib—Decreased appetite—Etoposide—peripheral nervous system neoplasm	0.000218	0.000586	CcSEcCtD
Trametinib—Renal failure—Epirubicin—peripheral nervous system neoplasm	0.000217	0.000583	CcSEcCtD
Trametinib—Gastrointestinal disorder—Etoposide—peripheral nervous system neoplasm	0.000216	0.000582	CcSEcCtD
Trametinib—Body temperature increased—Cisplatin—peripheral nervous system neoplasm	0.000216	0.000582	CcSEcCtD
Trametinib—Fatigue—Etoposide—peripheral nervous system neoplasm	0.000216	0.000582	CcSEcCtD
Trametinib—Stomatitis—Epirubicin—peripheral nervous system neoplasm	0.000215	0.000578	CcSEcCtD
Trametinib—Constipation—Etoposide—peripheral nervous system neoplasm	0.000214	0.000577	CcSEcCtD
Trametinib—Urinary tract infection—Epirubicin—peripheral nervous system neoplasm	0.000214	0.000576	CcSEcCtD
Trametinib—Neutropenia—Doxorubicin—peripheral nervous system neoplasm	0.000214	0.000575	CcSEcCtD
Trametinib—Dizziness—Alitretinoin—peripheral nervous system neoplasm	0.000212	0.000571	CcSEcCtD
Trametinib—Diarrhoea—Vincristine—peripheral nervous system neoplasm	0.000212	0.00057	CcSEcCtD
Trametinib—Haematuria—Epirubicin—peripheral nervous system neoplasm	0.00021	0.000565	CcSEcCtD
Trametinib—Epistaxis—Epirubicin—peripheral nervous system neoplasm	0.000208	0.000559	CcSEcCtD
Trametinib—Hyperglycaemia—Doxorubicin—peripheral nervous system neoplasm	0.000206	0.000555	CcSEcCtD
Trametinib—Nausea—Dactinomycin—peripheral nervous system neoplasm	0.000206	0.000554	CcSEcCtD
Trametinib—Gastrointestinal pain—Etoposide—peripheral nervous system neoplasm	0.000205	0.000552	CcSEcCtD
Trametinib—Dizziness—Vincristine—peripheral nervous system neoplasm	0.000205	0.000551	CcSEcCtD
Trametinib—Vomiting—Alitretinoin—peripheral nervous system neoplasm	0.000204	0.000549	CcSEcCtD
Trametinib—Infestation NOS—Doxorubicin—peripheral nervous system neoplasm	0.000204	0.000549	CcSEcCtD
Trametinib—Infestation—Doxorubicin—peripheral nervous system neoplasm	0.000204	0.000549	CcSEcCtD
Trametinib—Rash—Alitretinoin—peripheral nervous system neoplasm	0.000203	0.000545	CcSEcCtD
Trametinib—Dermatitis—Alitretinoin—peripheral nervous system neoplasm	0.000202	0.000544	CcSEcCtD
Trametinib—Bradycardia—Epirubicin—peripheral nervous system neoplasm	0.000201	0.000542	CcSEcCtD
Trametinib—Headache—Alitretinoin—peripheral nervous system neoplasm	0.000201	0.000541	CcSEcCtD
Trametinib—Renal failure—Doxorubicin—peripheral nervous system neoplasm	0.0002	0.000539	CcSEcCtD
Trametinib—Haemoglobin—Epirubicin—peripheral nervous system neoplasm	0.000199	0.000535	CcSEcCtD
Trametinib—Stomatitis—Doxorubicin—peripheral nervous system neoplasm	0.000199	0.000535	CcSEcCtD
Trametinib—Abdominal pain—Etoposide—peripheral nervous system neoplasm	0.000198	0.000533	CcSEcCtD
Trametinib—Body temperature increased—Etoposide—peripheral nervous system neoplasm	0.000198	0.000533	CcSEcCtD
Trametinib—Urinary tract infection—Doxorubicin—peripheral nervous system neoplasm	0.000198	0.000533	CcSEcCtD
Trametinib—Haemorrhage—Epirubicin—peripheral nervous system neoplasm	0.000198	0.000532	CcSEcCtD
Trametinib—Vomiting—Vincristine—peripheral nervous system neoplasm	0.000197	0.000529	CcSEcCtD
Trametinib—Asthenia—Cisplatin—peripheral nervous system neoplasm	0.000196	0.000528	CcSEcCtD
Trametinib—Urinary tract disorder—Epirubicin—peripheral nervous system neoplasm	0.000195	0.000526	CcSEcCtD
Trametinib—Rash—Vincristine—peripheral nervous system neoplasm	0.000195	0.000525	CcSEcCtD
Trametinib—Dermatitis—Vincristine—peripheral nervous system neoplasm	0.000195	0.000524	CcSEcCtD
Trametinib—Oedema peripheral—Epirubicin—peripheral nervous system neoplasm	0.000195	0.000524	CcSEcCtD
Trametinib—Haematuria—Doxorubicin—peripheral nervous system neoplasm	0.000194	0.000523	CcSEcCtD
Trametinib—Connective tissue disorder—Epirubicin—peripheral nervous system neoplasm	0.000194	0.000523	CcSEcCtD
Trametinib—Urethral disorder—Epirubicin—peripheral nervous system neoplasm	0.000194	0.000522	CcSEcCtD
Trametinib—Headache—Vincristine—peripheral nervous system neoplasm	0.000194	0.000522	CcSEcCtD
Trametinib—Epistaxis—Doxorubicin—peripheral nervous system neoplasm	0.000192	0.000517	CcSEcCtD
Trametinib—Nausea—Alitretinoin—peripheral nervous system neoplasm	0.000191	0.000513	CcSEcCtD
Trametinib—Diarrhoea—Cisplatin—peripheral nervous system neoplasm	0.000187	0.000504	CcSEcCtD
Trametinib—Bradycardia—Doxorubicin—peripheral nervous system neoplasm	0.000186	0.000501	CcSEcCtD
Trametinib—Eye disorder—Epirubicin—peripheral nervous system neoplasm	0.000185	0.000497	CcSEcCtD
Trametinib—Haemoglobin—Doxorubicin—peripheral nervous system neoplasm	0.000184	0.000495	CcSEcCtD
Trametinib—Nausea—Vincristine—peripheral nervous system neoplasm	0.000184	0.000495	CcSEcCtD
Trametinib—Cardiac disorder—Epirubicin—peripheral nervous system neoplasm	0.000184	0.000494	CcSEcCtD
Trametinib—Haemorrhage—Doxorubicin—peripheral nervous system neoplasm	0.000183	0.000492	CcSEcCtD
Trametinib—Urinary tract disorder—Doxorubicin—peripheral nervous system neoplasm	0.000181	0.000486	CcSEcCtD
Trametinib—Oedema peripheral—Doxorubicin—peripheral nervous system neoplasm	0.00018	0.000485	CcSEcCtD
Trametinib—Asthenia—Etoposide—peripheral nervous system neoplasm	0.00018	0.000484	CcSEcCtD
Trametinib—Connective tissue disorder—Doxorubicin—peripheral nervous system neoplasm	0.00018	0.000484	CcSEcCtD
Trametinib—Angiopathy—Epirubicin—peripheral nervous system neoplasm	0.00018	0.000483	CcSEcCtD
Trametinib—Urethral disorder—Doxorubicin—peripheral nervous system neoplasm	0.000179	0.000483	CcSEcCtD
Trametinib—Mediastinal disorder—Epirubicin—peripheral nervous system neoplasm	0.000178	0.00048	CcSEcCtD
Trametinib—Chills—Epirubicin—peripheral nervous system neoplasm	0.000178	0.000477	CcSEcCtD
Trametinib—Pruritus—Etoposide—peripheral nervous system neoplasm	0.000177	0.000477	CcSEcCtD
Trametinib—Arrhythmia—Epirubicin—peripheral nervous system neoplasm	0.000177	0.000475	CcSEcCtD
Trametinib—Vomiting—Cisplatin—peripheral nervous system neoplasm	0.000174	0.000468	CcSEcCtD
Trametinib—Mental disorder—Epirubicin—peripheral nervous system neoplasm	0.000173	0.000466	CcSEcCtD
Trametinib—Rash—Cisplatin—peripheral nervous system neoplasm	0.000173	0.000464	CcSEcCtD
Trametinib—Dermatitis—Cisplatin—peripheral nervous system neoplasm	0.000172	0.000464	CcSEcCtD
Trametinib—Erythema—Epirubicin—peripheral nervous system neoplasm	0.000172	0.000463	CcSEcCtD
Trametinib—Malnutrition—Epirubicin—peripheral nervous system neoplasm	0.000172	0.000463	CcSEcCtD
Trametinib—Diarrhoea—Etoposide—peripheral nervous system neoplasm	0.000172	0.000461	CcSEcCtD
Trametinib—Eye disorder—Doxorubicin—peripheral nervous system neoplasm	0.000171	0.00046	CcSEcCtD
Trametinib—Cardiac disorder—Doxorubicin—peripheral nervous system neoplasm	0.00017	0.000457	CcSEcCtD
Trametinib—Dysgeusia—Epirubicin—peripheral nervous system neoplasm	0.000169	0.000454	CcSEcCtD
Trametinib—Back pain—Epirubicin—peripheral nervous system neoplasm	0.000167	0.000448	CcSEcCtD
Trametinib—Angiopathy—Doxorubicin—peripheral nervous system neoplasm	0.000166	0.000447	CcSEcCtD
Trametinib—Dizziness—Etoposide—peripheral nervous system neoplasm	0.000166	0.000446	CcSEcCtD
Trametinib—Muscle spasms—Epirubicin—peripheral nervous system neoplasm	0.000166	0.000445	CcSEcCtD
Trametinib—Mediastinal disorder—Doxorubicin—peripheral nervous system neoplasm	0.000165	0.000444	CcSEcCtD
Trametinib—Chills—Doxorubicin—peripheral nervous system neoplasm	0.000164	0.000442	CcSEcCtD
Trametinib—Arrhythmia—Doxorubicin—peripheral nervous system neoplasm	0.000164	0.00044	CcSEcCtD
Trametinib—Nausea—Cisplatin—peripheral nervous system neoplasm	0.000163	0.000437	CcSEcCtD
Trametinib—Vision blurred—Epirubicin—peripheral nervous system neoplasm	0.000162	0.000437	CcSEcCtD
Trametinib—Mental disorder—Doxorubicin—peripheral nervous system neoplasm	0.00016	0.000431	CcSEcCtD
Trametinib—Vomiting—Etoposide—peripheral nervous system neoplasm	0.000159	0.000429	CcSEcCtD
Trametinib—Erythema—Doxorubicin—peripheral nervous system neoplasm	0.000159	0.000429	CcSEcCtD
Trametinib—Malnutrition—Doxorubicin—peripheral nervous system neoplasm	0.000159	0.000429	CcSEcCtD
Trametinib—Anaemia—Epirubicin—peripheral nervous system neoplasm	0.000159	0.000428	CcSEcCtD
Trametinib—Rash—Etoposide—peripheral nervous system neoplasm	0.000158	0.000425	CcSEcCtD
Trametinib—Dermatitis—Etoposide—peripheral nervous system neoplasm	0.000158	0.000425	CcSEcCtD
Trametinib—Headache—Etoposide—peripheral nervous system neoplasm	0.000157	0.000423	CcSEcCtD
Trametinib—Dysgeusia—Doxorubicin—peripheral nervous system neoplasm	0.000156	0.00042	CcSEcCtD
Trametinib—Leukopenia—Epirubicin—peripheral nervous system neoplasm	0.000154	0.000415	CcSEcCtD
Trametinib—Back pain—Doxorubicin—peripheral nervous system neoplasm	0.000154	0.000415	CcSEcCtD
Trametinib—Muscle spasms—Doxorubicin—peripheral nervous system neoplasm	0.000153	0.000412	CcSEcCtD
Trametinib—Cough—Epirubicin—peripheral nervous system neoplasm	0.00015	0.000404	CcSEcCtD
Trametinib—Vision blurred—Doxorubicin—peripheral nervous system neoplasm	0.00015	0.000404	CcSEcCtD
Trametinib—Nausea—Etoposide—peripheral nervous system neoplasm	0.000149	0.000401	CcSEcCtD
Trametinib—Hypertension—Epirubicin—peripheral nervous system neoplasm	0.000149	0.0004	CcSEcCtD
Trametinib—Anaemia—Doxorubicin—peripheral nervous system neoplasm	0.000147	0.000396	CcSEcCtD
Trametinib—Arthralgia—Epirubicin—peripheral nervous system neoplasm	0.000147	0.000394	CcSEcCtD
Trametinib—Myalgia—Epirubicin—peripheral nervous system neoplasm	0.000147	0.000394	CcSEcCtD
Trametinib—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—peripheral nervous system neoplasm	0.000146	0.000392	CcSEcCtD
Trametinib—Dry mouth—Epirubicin—peripheral nervous system neoplasm	0.000143	0.000386	CcSEcCtD
Trametinib—Leukopenia—Doxorubicin—peripheral nervous system neoplasm	0.000143	0.000384	CcSEcCtD
Trametinib—Oedema—Epirubicin—peripheral nervous system neoplasm	0.000141	0.000378	CcSEcCtD
Trametinib—Infection—Epirubicin—peripheral nervous system neoplasm	0.00014	0.000376	CcSEcCtD
Trametinib—Cough—Doxorubicin—peripheral nervous system neoplasm	0.000139	0.000374	CcSEcCtD
Trametinib—Nervous system disorder—Epirubicin—peripheral nervous system neoplasm	0.000138	0.000371	CcSEcCtD
Trametinib—Thrombocytopenia—Epirubicin—peripheral nervous system neoplasm	0.000138	0.00037	CcSEcCtD
Trametinib—Hypertension—Doxorubicin—peripheral nervous system neoplasm	0.000138	0.00037	CcSEcCtD
Trametinib—Skin disorder—Epirubicin—peripheral nervous system neoplasm	0.000137	0.000367	CcSEcCtD
Trametinib—Hyperhidrosis—Epirubicin—peripheral nervous system neoplasm	0.000136	0.000365	CcSEcCtD
Trametinib—Myalgia—Doxorubicin—peripheral nervous system neoplasm	0.000136	0.000365	CcSEcCtD
Trametinib—Arthralgia—Doxorubicin—peripheral nervous system neoplasm	0.000136	0.000365	CcSEcCtD
Trametinib—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—peripheral nervous system neoplasm	0.000135	0.000362	CcSEcCtD
Trametinib—Dry mouth—Doxorubicin—peripheral nervous system neoplasm	0.000133	0.000357	CcSEcCtD
Trametinib—Oedema—Doxorubicin—peripheral nervous system neoplasm	0.00013	0.00035	CcSEcCtD
Trametinib—Infection—Doxorubicin—peripheral nervous system neoplasm	0.000129	0.000348	CcSEcCtD
Trametinib—Musculoskeletal discomfort—Epirubicin—peripheral nervous system neoplasm	0.000128	0.000344	CcSEcCtD
Trametinib—Nervous system disorder—Doxorubicin—peripheral nervous system neoplasm	0.000128	0.000343	CcSEcCtD
Trametinib—Thrombocytopenia—Doxorubicin—peripheral nervous system neoplasm	0.000127	0.000343	CcSEcCtD
Trametinib—Insomnia—Epirubicin—peripheral nervous system neoplasm	0.000127	0.000342	CcSEcCtD
Trametinib—Skin disorder—Doxorubicin—peripheral nervous system neoplasm	0.000126	0.00034	CcSEcCtD
Trametinib—Hyperhidrosis—Doxorubicin—peripheral nervous system neoplasm	0.000126	0.000338	CcSEcCtD
Trametinib—Decreased appetite—Epirubicin—peripheral nervous system neoplasm	0.000122	0.000329	CcSEcCtD
Trametinib—Gastrointestinal disorder—Epirubicin—peripheral nervous system neoplasm	0.000121	0.000326	CcSEcCtD
Trametinib—Fatigue—Epirubicin—peripheral nervous system neoplasm	0.000121	0.000326	CcSEcCtD
Trametinib—Constipation—Epirubicin—peripheral nervous system neoplasm	0.00012	0.000323	CcSEcCtD
Trametinib—Musculoskeletal discomfort—Doxorubicin—peripheral nervous system neoplasm	0.000118	0.000319	CcSEcCtD
Trametinib—Insomnia—Doxorubicin—peripheral nervous system neoplasm	0.000118	0.000316	CcSEcCtD
Trametinib—Gastrointestinal pain—Epirubicin—peripheral nervous system neoplasm	0.000115	0.000309	CcSEcCtD
Trametinib—MAP2K1—Integrin-mediated Cell Adhesion—AKT1—peripheral nervous system neoplasm	0.000115	0.000344	CbGpPWpGaD
Trametinib—Decreased appetite—Doxorubicin—peripheral nervous system neoplasm	0.000113	0.000304	CcSEcCtD
Trametinib—MAP2K1—Toll-like Receptor Signaling Pathway—AKT1—peripheral nervous system neoplasm	0.000113	0.000339	CbGpPWpGaD
Trametinib—MAP2K1—Immune System—CD34—peripheral nervous system neoplasm	0.000113	0.000338	CbGpPWpGaD
Trametinib—MAP2K1—Fc epsilon receptor (FCERI) signaling—NRAS—peripheral nervous system neoplasm	0.000112	0.000337	CbGpPWpGaD
Trametinib—MAP2K1—DAP12 interactions—NRAS—peripheral nervous system neoplasm	0.000112	0.000337	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by FGFR in disease—NRAS—peripheral nervous system neoplasm	0.000112	0.000337	CbGpPWpGaD
Trametinib—Gastrointestinal disorder—Doxorubicin—peripheral nervous system neoplasm	0.000112	0.000302	CcSEcCtD
Trametinib—Fatigue—Doxorubicin—peripheral nervous system neoplasm	0.000112	0.000302	CcSEcCtD
Trametinib—MAP2K1—Signaling by EGFR—NRAS—peripheral nervous system neoplasm	0.000111	0.000334	CbGpPWpGaD
Trametinib—Constipation—Doxorubicin—peripheral nervous system neoplasm	0.000111	0.000299	CcSEcCtD
Trametinib—Abdominal pain—Epirubicin—peripheral nervous system neoplasm	0.000111	0.000299	CcSEcCtD
Trametinib—Body temperature increased—Epirubicin—peripheral nervous system neoplasm	0.000111	0.000299	CcSEcCtD
Trametinib—MAP2K1—Signaling by EGFR in Cancer—NRAS—peripheral nervous system neoplasm	0.00011	0.000331	CbGpPWpGaD
Trametinib—MAP2K1—ErbB1 downstream signaling—AKT1—peripheral nervous system neoplasm	0.00011	0.000331	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by PDGF—NRAS—peripheral nervous system neoplasm	0.00011	0.00033	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by VEGF—AKT1—peripheral nervous system neoplasm	0.00011	0.000329	CbGpPWpGaD
Trametinib—MAP2K1—MAPK Signaling Pathway—MYC—peripheral nervous system neoplasm	0.000109	0.000328	CbGpPWpGaD
Trametinib—MAP2K1—TGF-beta Signaling Pathway—TP53—peripheral nervous system neoplasm	0.000109	0.000326	CbGpPWpGaD
Trametinib—MAP2K1—PDGFR-beta signaling pathway—HRAS—peripheral nervous system neoplasm	0.000109	0.000326	CbGpPWpGaD
Trametinib—MAP2K1—VEGFA-VEGFR2 Pathway—AKT1—peripheral nervous system neoplasm	0.000109	0.000326	CbGpPWpGaD
Trametinib—MAP2K1—Immune System—PPP3R1—peripheral nervous system neoplasm	0.000108	0.000325	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by NGF—ERBB2—peripheral nervous system neoplasm	0.000108	0.000323	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—NTS—peripheral nervous system neoplasm	0.000107	0.000321	CbGpPWpGaD
Trametinib—MAP2K2—Disease—PPP3R1—peripheral nervous system neoplasm	0.000107	0.000321	CbGpPWpGaD
Trametinib—MAP2K2—NGF signalling via TRKA from the plasma membrane—NRAS—peripheral nervous system neoplasm	0.000106	0.000319	CbGpPWpGaD
Trametinib—Gastrointestinal pain—Doxorubicin—peripheral nervous system neoplasm	0.000106	0.000286	CcSEcCtD
Trametinib—MAP2K2—Signaling by SCF-KIT—HRAS—peripheral nervous system neoplasm	0.000105	0.000316	CbGpPWpGaD
Trametinib—MAP2K2—BDNF signaling pathway—HRAS—peripheral nervous system neoplasm	0.000104	0.000311	CbGpPWpGaD
Trametinib—MAP2K2—Gastrin-CREB signalling pathway via PKC and MAPK—NRAS—peripheral nervous system neoplasm	0.000103	0.000309	CbGpPWpGaD
Trametinib—Abdominal pain—Doxorubicin—peripheral nervous system neoplasm	0.000103	0.000277	CcSEcCtD
Trametinib—Body temperature increased—Doxorubicin—peripheral nervous system neoplasm	0.000103	0.000277	CcSEcCtD
Trametinib—MAP2K2—Signaling Pathways—CD55—peripheral nervous system neoplasm	0.000103	0.000308	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by VEGF—AKT1—peripheral nervous system neoplasm	0.000103	0.000308	CbGpPWpGaD
Trametinib—MAP2K2—Immune System—NCAM1—peripheral nervous system neoplasm	0.000102	0.000307	CbGpPWpGaD
Trametinib—MAP2K2—Downstream signaling of activated FGFR—HRAS—peripheral nervous system neoplasm	0.000101	0.000303	CbGpPWpGaD
Trametinib—Asthenia—Epirubicin—peripheral nervous system neoplasm	0.000101	0.000271	CcSEcCtD
Trametinib—MAP2K1—Signaling by NGF—ERBB2—peripheral nervous system neoplasm	0.000101	0.000302	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—NTS—peripheral nervous system neoplasm	0.0001	0.000301	CbGpPWpGaD
Trametinib—MAP2K1—Disease—PPP3R1—peripheral nervous system neoplasm	0.0001	0.0003	CbGpPWpGaD
Trametinib—MAP2K1—NGF signalling via TRKA from the plasma membrane—NRAS—peripheral nervous system neoplasm	9.96e-05	0.000299	CbGpPWpGaD
Trametinib—Pruritus—Epirubicin—peripheral nervous system neoplasm	9.94e-05	0.000267	CcSEcCtD
Trametinib—MAP2K2—Signaling by ERBB4—HRAS—peripheral nervous system neoplasm	9.93e-05	0.000298	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by SCF-KIT—HRAS—peripheral nervous system neoplasm	9.86e-05	0.000296	CbGpPWpGaD
Trametinib—MAP2K1—Integrated Pancreatic Cancer Pathway—MYC—peripheral nervous system neoplasm	9.85e-05	0.000296	CbGpPWpGaD
Trametinib—MAP2K2—TGF-beta Signaling Pathway—AKT1—peripheral nervous system neoplasm	9.81e-05	0.000295	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by NGF—CASP3—peripheral nervous system neoplasm	9.76e-05	0.000293	CbGpPWpGaD
Trametinib—MAP2K2—Axon guidance—ERBB2—peripheral nervous system neoplasm	9.74e-05	0.000292	CbGpPWpGaD
Trametinib—MAP2K1—BDNF signaling pathway—HRAS—peripheral nervous system neoplasm	9.7e-05	0.000291	CbGpPWpGaD
Trametinib—MAP2K1—Gastrin-CREB signalling pathway via PKC and MAPK—NRAS—peripheral nervous system neoplasm	9.62e-05	0.000289	CbGpPWpGaD
Trametinib—Diarrhoea—Epirubicin—peripheral nervous system neoplasm	9.62e-05	0.000259	CcSEcCtD
Trametinib—MAP2K1—Signaling Pathways—CD55—peripheral nervous system neoplasm	9.6e-05	0.000288	CbGpPWpGaD
Trametinib—MAP2K2—MAPK Signaling Pathway—TP53—peripheral nervous system neoplasm	9.58e-05	0.000288	CbGpPWpGaD
Trametinib—MAP2K1—Immune System—NCAM1—peripheral nervous system neoplasm	9.57e-05	0.000287	CbGpPWpGaD
Trametinib—MAP2K2—Insulin Signaling—HRAS—peripheral nervous system neoplasm	9.53e-05	0.000286	CbGpPWpGaD
Trametinib—MAP2K2—Developmental Biology—MET—peripheral nervous system neoplasm	9.51e-05	0.000285	CbGpPWpGaD
Trametinib—MAP2K2—Downstream signal transduction—HRAS—peripheral nervous system neoplasm	9.48e-05	0.000285	CbGpPWpGaD
Trametinib—MAP2K1—Downstream signaling of activated FGFR—HRAS—peripheral nervous system neoplasm	9.44e-05	0.000283	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by FGFR—HRAS—peripheral nervous system neoplasm	9.44e-05	0.000283	CbGpPWpGaD
Trametinib—MAP2K2—EGF/EGFR Signaling Pathway—HRAS—peripheral nervous system neoplasm	9.44e-05	0.000283	CbGpPWpGaD
Trametinib—MAP2K2—Regulation of toll-like receptor signaling pathway—AKT1—peripheral nervous system neoplasm	9.42e-05	0.000283	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by ERBB2—HRAS—peripheral nervous system neoplasm	9.39e-05	0.000282	CbGpPWpGaD
Trametinib—MAP2K2—DAP12 signaling—HRAS—peripheral nervous system neoplasm	9.34e-05	0.00028	CbGpPWpGaD
Trametinib—Asthenia—Doxorubicin—peripheral nervous system neoplasm	9.33e-05	0.000251	CcSEcCtD
Trametinib—MAP2K2—Signaling by SCF-KIT—AKT1—peripheral nervous system neoplasm	9.31e-05	0.000279	CbGpPWpGaD
Trametinib—Dizziness—Epirubicin—peripheral nervous system neoplasm	9.29e-05	0.00025	CcSEcCtD
Trametinib—MAP2K1—Signaling by ERBB4—HRAS—peripheral nervous system neoplasm	9.29e-05	0.000279	CbGpPWpGaD
Trametinib—MAP2K2—Disease—ENO2—peripheral nervous system neoplasm	9.26e-05	0.000278	CbGpPWpGaD
Trametinib—Pruritus—Doxorubicin—peripheral nervous system neoplasm	9.2e-05	0.000248	CcSEcCtD
Trametinib—MAP2K1—TGF-beta Signaling Pathway—AKT1—peripheral nervous system neoplasm	9.18e-05	0.000276	CbGpPWpGaD
Trametinib—MAP2K2—BDNF signaling pathway—AKT1—peripheral nervous system neoplasm	9.15e-05	0.000275	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by NGF—CASP3—peripheral nervous system neoplasm	9.14e-05	0.000274	CbGpPWpGaD
Trametinib—MAP2K1—Axon guidance—ERBB2—peripheral nervous system neoplasm	9.11e-05	0.000273	CbGpPWpGaD
Trametinib—MAP2K1—MAPK Signaling Pathway—TP53—peripheral nervous system neoplasm	8.97e-05	0.000269	CbGpPWpGaD
Trametinib—Vomiting—Epirubicin—peripheral nervous system neoplasm	8.94e-05	0.00024	CcSEcCtD
Trametinib—MAP2K1—Insulin Signaling—HRAS—peripheral nervous system neoplasm	8.92e-05	0.000268	CbGpPWpGaD
Trametinib—MAP2K2—Downstream signaling of activated FGFR—AKT1—peripheral nervous system neoplasm	8.91e-05	0.000267	CbGpPWpGaD
Trametinib—Diarrhoea—Doxorubicin—peripheral nervous system neoplasm	8.9e-05	0.000239	CcSEcCtD
Trametinib—MAP2K1—Developmental Biology—MET—peripheral nervous system neoplasm	8.89e-05	0.000267	CbGpPWpGaD
Trametinib—MAP2K1—Downstream signal transduction—HRAS—peripheral nervous system neoplasm	8.87e-05	0.000266	CbGpPWpGaD
Trametinib—Rash—Epirubicin—peripheral nervous system neoplasm	8.86e-05	0.000238	CcSEcCtD
Trametinib—Dermatitis—Epirubicin—peripheral nervous system neoplasm	8.85e-05	0.000238	CcSEcCtD
Trametinib—MAP2K1—EGF/EGFR Signaling Pathway—HRAS—peripheral nervous system neoplasm	8.83e-05	0.000265	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by FGFR—HRAS—peripheral nervous system neoplasm	8.83e-05	0.000265	CbGpPWpGaD
Trametinib—MAP2K1—Regulation of toll-like receptor signaling pathway—AKT1—peripheral nervous system neoplasm	8.81e-05	0.000264	CbGpPWpGaD
Trametinib—Headache—Epirubicin—peripheral nervous system neoplasm	8.81e-05	0.000237	CcSEcCtD
Trametinib—MAP2K2—Developmental Biology—PTPN11—peripheral nervous system neoplasm	8.79e-05	0.000264	CbGpPWpGaD
Trametinib—MAP2K2—Fc epsilon receptor (FCERI) signaling—HRAS—peripheral nervous system neoplasm	8.79e-05	0.000264	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by FGFR in disease—HRAS—peripheral nervous system neoplasm	8.79e-05	0.000264	CbGpPWpGaD
Trametinib—MAP2K2—DAP12 interactions—HRAS—peripheral nervous system neoplasm	8.79e-05	0.000264	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by ERBB2—HRAS—peripheral nervous system neoplasm	8.78e-05	0.000264	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by ERBB4—AKT1—peripheral nervous system neoplasm	8.77e-05	0.000263	CbGpPWpGaD
Trametinib—MAP2K1—DAP12 signaling—HRAS—peripheral nervous system neoplasm	8.74e-05	0.000262	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by EGFR—HRAS—peripheral nervous system neoplasm	8.71e-05	0.000261	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by SCF-KIT—AKT1—peripheral nervous system neoplasm	8.71e-05	0.000261	CbGpPWpGaD
Trametinib—MAP2K1—Disease—ENO2—peripheral nervous system neoplasm	8.67e-05	0.00026	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by EGFR in Cancer—HRAS—peripheral nervous system neoplasm	8.63e-05	0.000259	CbGpPWpGaD
Trametinib—Dizziness—Doxorubicin—peripheral nervous system neoplasm	8.6e-05	0.000231	CcSEcCtD
Trametinib—MAP2K2—Signaling by PDGF—HRAS—peripheral nervous system neoplasm	8.6e-05	0.000258	CbGpPWpGaD
Trametinib—MAP2K1—BDNF signaling pathway—AKT1—peripheral nervous system neoplasm	8.56e-05	0.000257	CbGpPWpGaD
Trametinib—MAP2K2—Insulin Signaling—AKT1—peripheral nervous system neoplasm	8.41e-05	0.000253	CbGpPWpGaD
Trametinib—MAP2K2—Downstream signal transduction—AKT1—peripheral nervous system neoplasm	8.37e-05	0.000251	CbGpPWpGaD
Trametinib—Nausea—Epirubicin—peripheral nervous system neoplasm	8.35e-05	0.000225	CcSEcCtD
Trametinib—CYP2C8—Metabolism—HSD17B12—peripheral nervous system neoplasm	8.34e-05	0.00025	CbGpPWpGaD
Trametinib—MAP2K1—Downstream signaling of activated FGFR—AKT1—peripheral nervous system neoplasm	8.33e-05	0.00025	CbGpPWpGaD
Trametinib—MAP2K2—EGF/EGFR Signaling Pathway—AKT1—peripheral nervous system neoplasm	8.33e-05	0.00025	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by FGFR—AKT1—peripheral nervous system neoplasm	8.33e-05	0.00025	CbGpPWpGaD
Trametinib—MAP2K2—Cytokine Signaling in Immune system—NRAS—peripheral nervous system neoplasm	8.32e-05	0.00025	CbGpPWpGaD
Trametinib—MAP2K2—Focal Adhesion—HRAS—peripheral nervous system neoplasm	8.31e-05	0.000249	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by ERBB2—AKT1—peripheral nervous system neoplasm	8.29e-05	0.000249	CbGpPWpGaD
Trametinib—Vomiting—Doxorubicin—peripheral nervous system neoplasm	8.27e-05	0.000222	CcSEcCtD
Trametinib—MAP2K2—DAP12 signaling—AKT1—peripheral nervous system neoplasm	8.25e-05	0.000248	CbGpPWpGaD
Trametinib—MAP2K1—Developmental Biology—PTPN11—peripheral nervous system neoplasm	8.22e-05	0.000247	CbGpPWpGaD
Trametinib—MAP2K1—Fc epsilon receptor (FCERI) signaling—HRAS—peripheral nervous system neoplasm	8.22e-05	0.000247	CbGpPWpGaD
Trametinib—MAP2K1—DAP12 interactions—HRAS—peripheral nervous system neoplasm	8.22e-05	0.000247	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by FGFR in disease—HRAS—peripheral nervous system neoplasm	8.22e-05	0.000247	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by ERBB4—AKT1—peripheral nervous system neoplasm	8.2e-05	0.000246	CbGpPWpGaD
Trametinib—Rash—Doxorubicin—peripheral nervous system neoplasm	8.2e-05	0.000221	CcSEcCtD
Trametinib—Dermatitis—Doxorubicin—peripheral nervous system neoplasm	8.19e-05	0.00022	CcSEcCtD
Trametinib—MAP2K2—Signaling by NGF—NRAS—peripheral nervous system neoplasm	8.18e-05	0.000246	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by EGFR—HRAS—peripheral nervous system neoplasm	8.15e-05	0.000245	CbGpPWpGaD
Trametinib—Headache—Doxorubicin—peripheral nervous system neoplasm	8.15e-05	0.000219	CcSEcCtD
Trametinib—MAP2K2—Signaling by GPCR—KNG1—peripheral nervous system neoplasm	8.14e-05	0.000244	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—VIP—peripheral nervous system neoplasm	8.11e-05	0.000244	CbGpPWpGaD
Trametinib—MAP2K2—MAPK Signaling Pathway—AKT1—peripheral nervous system neoplasm	8.09e-05	0.000243	CbGpPWpGaD
Trametinib—MAP2K1—Integrated Pancreatic Cancer Pathway—TP53—peripheral nervous system neoplasm	8.09e-05	0.000243	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by EGFR in Cancer—HRAS—peripheral nervous system neoplasm	8.08e-05	0.000242	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by PDGF—HRAS—peripheral nervous system neoplasm	8.04e-05	0.000241	CbGpPWpGaD
Trametinib—MAP2K2—Immune System—IFNB1—peripheral nervous system neoplasm	8.03e-05	0.000241	CbGpPWpGaD
Trametinib—MAP2K1—Insulin Signaling—AKT1—peripheral nervous system neoplasm	7.87e-05	0.000236	CbGpPWpGaD
Trametinib—MAP2K1—Downstream signal transduction—AKT1—peripheral nervous system neoplasm	7.83e-05	0.000235	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by FGFR—AKT1—peripheral nervous system neoplasm	7.79e-05	0.000234	CbGpPWpGaD
Trametinib—MAP2K1—EGF/EGFR Signaling Pathway—AKT1—peripheral nervous system neoplasm	7.79e-05	0.000234	CbGpPWpGaD
Trametinib—MAP2K1—Cytokine Signaling in Immune system—NRAS—peripheral nervous system neoplasm	7.79e-05	0.000234	CbGpPWpGaD
Trametinib—MAP2K2—NGF signalling via TRKA from the plasma membrane—HRAS—peripheral nervous system neoplasm	7.79e-05	0.000234	CbGpPWpGaD
Trametinib—MAP2K1—Focal Adhesion—HRAS—peripheral nervous system neoplasm	7.77e-05	0.000233	CbGpPWpGaD
Trametinib—MAP2K2—Innate Immune System—PTPN11—peripheral nervous system neoplasm	7.76e-05	0.000233	CbGpPWpGaD
Trametinib—MAP2K2—DAP12 interactions—AKT1—peripheral nervous system neoplasm	7.76e-05	0.000233	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by FGFR in disease—AKT1—peripheral nervous system neoplasm	7.76e-05	0.000233	CbGpPWpGaD
Trametinib—MAP2K2—Fc epsilon receptor (FCERI) signaling—AKT1—peripheral nervous system neoplasm	7.76e-05	0.000233	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by ERBB2—AKT1—peripheral nervous system neoplasm	7.76e-05	0.000233	CbGpPWpGaD
Trametinib—Nausea—Doxorubicin—peripheral nervous system neoplasm	7.73e-05	0.000208	CcSEcCtD
Trametinib—MAP2K1—DAP12 signaling—AKT1—peripheral nervous system neoplasm	7.72e-05	0.000232	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by EGFR—AKT1—peripheral nervous system neoplasm	7.69e-05	0.000231	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by NGF—NRAS—peripheral nervous system neoplasm	7.66e-05	0.00023	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by EGFR in Cancer—AKT1—peripheral nervous system neoplasm	7.62e-05	0.000229	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by GPCR—KNG1—peripheral nervous system neoplasm	7.62e-05	0.000229	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—VIP—peripheral nervous system neoplasm	7.59e-05	0.000228	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by PDGF—AKT1—peripheral nervous system neoplasm	7.59e-05	0.000228	CbGpPWpGaD
Trametinib—MAP2K1—MAPK Signaling Pathway—AKT1—peripheral nervous system neoplasm	7.57e-05	0.000227	CbGpPWpGaD
Trametinib—MAP2K2—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—peripheral nervous system neoplasm	7.52e-05	0.000226	CbGpPWpGaD
Trametinib—MAP2K1—Immune System—IFNB1—peripheral nervous system neoplasm	7.51e-05	0.000225	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—PPP3R1—peripheral nervous system neoplasm	7.49e-05	0.000225	CbGpPWpGaD
Trametinib—MAP2K2—Disease—SLC2A1—peripheral nervous system neoplasm	7.47e-05	0.000224	CbGpPWpGaD
Trametinib—MAP2K2—Axon guidance—NRAS—peripheral nervous system neoplasm	7.41e-05	0.000222	CbGpPWpGaD
Trametinib—MAP2K2—Focal Adhesion—AKT1—peripheral nervous system neoplasm	7.33e-05	0.00022	CbGpPWpGaD
Trametinib—MAP2K1—NGF signalling via TRKA from the plasma membrane—HRAS—peripheral nervous system neoplasm	7.28e-05	0.000219	CbGpPWpGaD
Trametinib—MAP2K1—Innate Immune System—PTPN11—peripheral nervous system neoplasm	7.26e-05	0.000218	CbGpPWpGaD
Trametinib—MAP2K1—DAP12 interactions—AKT1—peripheral nervous system neoplasm	7.26e-05	0.000218	CbGpPWpGaD
Trametinib—MAP2K1—Fc epsilon receptor (FCERI) signaling—AKT1—peripheral nervous system neoplasm	7.26e-05	0.000218	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by FGFR in disease—AKT1—peripheral nervous system neoplasm	7.26e-05	0.000218	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by EGFR—AKT1—peripheral nervous system neoplasm	7.2e-05	0.000216	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by EGFR in Cancer—AKT1—peripheral nervous system neoplasm	7.13e-05	0.000214	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by GPCR—GNAS—peripheral nervous system neoplasm	7.12e-05	0.000214	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by PDGF—AKT1—peripheral nervous system neoplasm	7.1e-05	0.000213	CbGpPWpGaD
Trametinib—MAP2K1—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—peripheral nervous system neoplasm	7.04e-05	0.000211	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—PPP3R1—peripheral nervous system neoplasm	7.01e-05	0.00021	CbGpPWpGaD
Trametinib—MAP2K1—Disease—SLC2A1—peripheral nervous system neoplasm	6.99e-05	0.00021	CbGpPWpGaD
Trametinib—MAP2K2—Developmental Biology—ERBB2—peripheral nervous system neoplasm	6.95e-05	0.000209	CbGpPWpGaD
Trametinib—MAP2K1—Axon guidance—NRAS—peripheral nervous system neoplasm	6.93e-05	0.000208	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism of lipids and lipoproteins—BCHE—peripheral nervous system neoplasm	6.93e-05	0.000208	CbGpPWpGaD
Trametinib—MAP2K2—NGF signalling via TRKA from the plasma membrane—AKT1—peripheral nervous system neoplasm	6.87e-05	0.000206	CbGpPWpGaD
Trametinib—MAP2K1—Focal Adhesion—AKT1—peripheral nervous system neoplasm	6.86e-05	0.000206	CbGpPWpGaD
Trametinib—MAP2K1—Integrated Pancreatic Cancer Pathway—AKT1—peripheral nervous system neoplasm	6.83e-05	0.000205	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by GPCR—GNAS—peripheral nervous system neoplasm	6.66e-05	0.0002	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—PPIP5K2—peripheral nervous system neoplasm	6.63e-05	0.000199	CbGpPWpGaD
Trametinib—MAP2K1—Developmental Biology—ERBB2—peripheral nervous system neoplasm	6.5e-05	0.000195	CbGpPWpGaD
Trametinib—MAP2K1—NGF signalling via TRKA from the plasma membrane—AKT1—peripheral nervous system neoplasm	6.43e-05	0.000193	CbGpPWpGaD
Trametinib—MAP2K2—Immune System—HGF—peripheral nervous system neoplasm	6.2e-05	0.000186	CbGpPWpGaD
Trametinib—MAP2K2—Innate Immune System—ERBB2—peripheral nervous system neoplasm	6.14e-05	0.000184	CbGpPWpGaD
Trametinib—MAP2K2—Cytokine Signaling in Immune system—HRAS—peripheral nervous system neoplasm	6.09e-05	0.000183	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—GNS—peripheral nervous system neoplasm	6.03e-05	0.000181	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by NGF—HRAS—peripheral nervous system neoplasm	5.99e-05	0.00018	CbGpPWpGaD
Trametinib—MAP2K1—Immune System—HGF—peripheral nervous system neoplasm	5.8e-05	0.000174	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—NME1—peripheral nervous system neoplasm	5.78e-05	0.000173	CbGpPWpGaD
Trametinib—MAP2K1—Innate Immune System—ERBB2—peripheral nervous system neoplasm	5.74e-05	0.000172	CbGpPWpGaD
Trametinib—MAP2K1—Cytokine Signaling in Immune system—HRAS—peripheral nervous system neoplasm	5.7e-05	0.000171	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—NTRK2—peripheral nervous system neoplasm	5.62e-05	0.000169	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by NGF—HRAS—peripheral nervous system neoplasm	5.6e-05	0.000168	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—COX2—peripheral nervous system neoplasm	5.56e-05	0.000167	CbGpPWpGaD
Trametinib—MAP2K2—Axon guidance—HRAS—peripheral nervous system neoplasm	5.42e-05	0.000163	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by NGF—AKT1—peripheral nervous system neoplasm	5.29e-05	0.000159	CbGpPWpGaD
Trametinib—MAP2K2—Developmental Biology—NRAS—peripheral nervous system neoplasm	5.29e-05	0.000159	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—NTRK2—peripheral nervous system neoplasm	5.26e-05	0.000158	CbGpPWpGaD
Trametinib—MAP2K1—Axon guidance—HRAS—peripheral nervous system neoplasm	5.07e-05	0.000152	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by GPCR—PTPN11—peripheral nervous system neoplasm	4.95e-05	0.000149	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by NGF—AKT1—peripheral nervous system neoplasm	4.95e-05	0.000148	CbGpPWpGaD
Trametinib—MAP2K1—Developmental Biology—NRAS—peripheral nervous system neoplasm	4.95e-05	0.000148	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—KNG1—peripheral nervous system neoplasm	4.81e-05	0.000144	CbGpPWpGaD
Trametinib—MAP2K2—Innate Immune System—NRAS—peripheral nervous system neoplasm	4.67e-05	0.00014	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by GPCR—PTPN11—peripheral nervous system neoplasm	4.63e-05	0.000139	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—NTRK1—peripheral nervous system neoplasm	4.59e-05	0.000138	CbGpPWpGaD
Trametinib—MAP2K2—Immune System—PTPN11—peripheral nervous system neoplasm	4.52e-05	0.000136	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—KNG1—peripheral nervous system neoplasm	4.5e-05	0.000135	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—HSD17B12—peripheral nervous system neoplasm	4.48e-05	0.000134	CbGpPWpGaD
Trametinib—MAP2K1—Innate Immune System—NRAS—peripheral nervous system neoplasm	4.37e-05	0.000131	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—NTRK1—peripheral nervous system neoplasm	4.29e-05	0.000129	CbGpPWpGaD
Trametinib—MAP2K1—Immune System—PTPN11—peripheral nervous system neoplasm	4.23e-05	0.000127	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—GNAS—peripheral nervous system neoplasm	4.21e-05	0.000126	CbGpPWpGaD
Trametinib—MAP2K2—Disease—PTPN11—peripheral nervous system neoplasm	4.18e-05	0.000125	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—GNAS—peripheral nervous system neoplasm	3.94e-05	0.000118	CbGpPWpGaD
Trametinib—MAP2K1—Disease—PTPN11—peripheral nervous system neoplasm	3.91e-05	0.000117	CbGpPWpGaD
Trametinib—MAP2K2—Developmental Biology—HRAS—peripheral nervous system neoplasm	3.87e-05	0.000116	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—ENO2—peripheral nervous system neoplasm	3.65e-05	0.00011	CbGpPWpGaD
Trametinib—MAP2K1—Developmental Biology—HRAS—peripheral nervous system neoplasm	3.62e-05	0.000109	CbGpPWpGaD
Trametinib—MAP2K2—Immune System—ERBB2—peripheral nervous system neoplasm	3.57e-05	0.000107	CbGpPWpGaD
Trametinib—MAP2K2—Innate Immune System—HRAS—peripheral nervous system neoplasm	3.42e-05	0.000103	CbGpPWpGaD
Trametinib—MAP2K2—Developmental Biology—AKT1—peripheral nervous system neoplasm	3.41e-05	0.000102	CbGpPWpGaD
Trametinib—MAP2K1—Immune System—ERBB2—peripheral nervous system neoplasm	3.34e-05	0.0001	CbGpPWpGaD
Trametinib—MAP2K2—Disease—ERBB2—peripheral nervous system neoplasm	3.3e-05	9.9e-05	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—GNS—peripheral nervous system neoplasm	3.24e-05	9.71e-05	CbGpPWpGaD
Trametinib—MAP2K1—Innate Immune System—HRAS—peripheral nervous system neoplasm	3.2e-05	9.59e-05	CbGpPWpGaD
Trametinib—MAP2K1—Developmental Biology—AKT1—peripheral nervous system neoplasm	3.19e-05	9.59e-05	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—NME1—peripheral nervous system neoplasm	3.1e-05	9.31e-05	CbGpPWpGaD
Trametinib—MAP2K1—Disease—ERBB2—peripheral nervous system neoplasm	3.09e-05	9.27e-05	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—BCHE—peripheral nervous system neoplasm	3.09e-05	9.26e-05	CbGpPWpGaD
Trametinib—MAP2K2—Innate Immune System—AKT1—peripheral nervous system neoplasm	3.02e-05	9.05e-05	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—COX2—peripheral nervous system neoplasm	2.99e-05	8.96e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by GPCR—NRAS—peripheral nervous system neoplasm	2.98e-05	8.93e-05	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—SLC2A1—peripheral nervous system neoplasm	2.94e-05	8.84e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—PTPN11—peripheral nervous system neoplasm	2.92e-05	8.78e-05	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—TH—peripheral nervous system neoplasm	2.9e-05	8.71e-05	CbGpPWpGaD
Trametinib—MAP2K1—Innate Immune System—AKT1—peripheral nervous system neoplasm	2.82e-05	8.47e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by GPCR—NRAS—peripheral nervous system neoplasm	2.78e-05	8.36e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—PTPN11—peripheral nervous system neoplasm	2.74e-05	8.21e-05	CbGpPWpGaD
Trametinib—MAP2K2—Immune System—NRAS—peripheral nervous system neoplasm	2.72e-05	8.16e-05	CbGpPWpGaD
Trametinib—MAP2K1—Immune System—NRAS—peripheral nervous system neoplasm	2.54e-05	7.64e-05	CbGpPWpGaD
Trametinib—MAP2K2—Disease—NRAS—peripheral nervous system neoplasm	2.51e-05	7.53e-05	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—GNAS—peripheral nervous system neoplasm	2.37e-05	7.11e-05	CbGpPWpGaD
Trametinib—MAP2K1—Disease—NRAS—peripheral nervous system neoplasm	2.35e-05	7.05e-05	CbGpPWpGaD
Trametinib—MAP2K2—Disease—MYC—peripheral nervous system neoplasm	2.34e-05	7.02e-05	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—ABCB1—peripheral nervous system neoplasm	2.32e-05	6.98e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—ERBB2—peripheral nervous system neoplasm	2.31e-05	6.94e-05	CbGpPWpGaD
Trametinib—MAP2K1—Disease—MYC—peripheral nervous system neoplasm	2.19e-05	6.57e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by GPCR—HRAS—peripheral nervous system neoplasm	2.18e-05	6.53e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—ERBB2—peripheral nervous system neoplasm	2.16e-05	6.49e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—CASP3—peripheral nervous system neoplasm	2.1e-05	6.3e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by GPCR—HRAS—peripheral nervous system neoplasm	2.04e-05	6.11e-05	CbGpPWpGaD
Trametinib—MAP2K2—Immune System—HRAS—peripheral nervous system neoplasm	1.99e-05	5.97e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—CASP3—peripheral nervous system neoplasm	1.96e-05	5.89e-05	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—ENO2—peripheral nervous system neoplasm	1.96e-05	5.88e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by GPCR—AKT1—peripheral nervous system neoplasm	1.92e-05	5.77e-05	CbGpPWpGaD
Trametinib—MAP2K1—Immune System—HRAS—peripheral nervous system neoplasm	1.86e-05	5.59e-05	CbGpPWpGaD
Trametinib—MAP2K2—Disease—HRAS—peripheral nervous system neoplasm	1.84e-05	5.51e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by GPCR—AKT1—peripheral nervous system neoplasm	1.8e-05	5.4e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—NRAS—peripheral nervous system neoplasm	1.76e-05	5.28e-05	CbGpPWpGaD
Trametinib—MAP2K2—Immune System—AKT1—peripheral nervous system neoplasm	1.76e-05	5.27e-05	CbGpPWpGaD
Trametinib—MAP2K1—Disease—HRAS—peripheral nervous system neoplasm	1.72e-05	5.16e-05	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—BCHE—peripheral nervous system neoplasm	1.66e-05	4.97e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—NRAS—peripheral nervous system neoplasm	1.64e-05	4.94e-05	CbGpPWpGaD
Trametinib—MAP2K1—Immune System—AKT1—peripheral nervous system neoplasm	1.64e-05	4.93e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—MYC—peripheral nervous system neoplasm	1.64e-05	4.91e-05	CbGpPWpGaD
Trametinib—MAP2K2—Disease—AKT1—peripheral nervous system neoplasm	1.62e-05	4.87e-05	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—SLC2A1—peripheral nervous system neoplasm	1.58e-05	4.74e-05	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—TH—peripheral nervous system neoplasm	1.56e-05	4.67e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—MYC—peripheral nervous system neoplasm	1.53e-05	4.6e-05	CbGpPWpGaD
Trametinib—MAP2K1—Disease—AKT1—peripheral nervous system neoplasm	1.52e-05	4.55e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—TP53—peripheral nervous system neoplasm	1.34e-05	4.04e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—HRAS—peripheral nervous system neoplasm	1.29e-05	3.86e-05	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—GNAS—peripheral nervous system neoplasm	1.27e-05	3.82e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—TP53—peripheral nervous system neoplasm	1.26e-05	3.78e-05	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—ABCB1—peripheral nervous system neoplasm	1.25e-05	3.74e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—HRAS—peripheral nervous system neoplasm	1.2e-05	3.61e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—AKT1—peripheral nervous system neoplasm	1.14e-05	3.41e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—AKT1—peripheral nervous system neoplasm	1.06e-05	3.19e-05	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—AKT1—peripheral nervous system neoplasm	6.39e-06	1.92e-05	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—AKT1—peripheral nervous system neoplasm	3.43e-06	1.03e-05	CbGpPWpGaD
